This is a follow-up study for people with Pulmonary Arterial Hypertension (PAH), a condition where the blood pressure in the lungs' arteries is too high. The study checks the long-term safety and effectiveness of a medicine called sotatercept (MK-7962) in adults who have already joined earlier sotatercept studies. Sotatercept helps improve blood flow and how well the heart works in people with PAH.

Key Points:

• The study is open-label, meaning all participants will know they are receiving sotatercept.
• Participants must have finished a previous sotatercept study and agree to regular visits and follow-ups.
• People cannot join if they missed many doses in prior studies or had serious side effects related to sotatercept.

Participants must also follow certain rules like using effective birth control if they are of childbearing potential and not donating blood or sperm during the study. All study-related visits and procedures are free, but there may be no additional compensation.